Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 1209-1216

  Kanavaros, P ^a,f   Vlychou, M ^b   Stefanaki, K ^a   Rontogianni, D ^c   Gaulard, P ^d   Pantelidaki, E ^c   Zois, M ^e   Darivianaki, K ^a   Georgoulias, V ^a   Boulland, M L ^d   Gorgoulis, V ^b   Kittas, C ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c EVANGELISMOS HOSPITAL   (Greece)

^d HENRI MONDOR HOSPITAL   (France)

^e Venizelion Hospital of Heraklion   (Greece)

^f NONE   (Greece)

Author keywords

Cytotoxic proteins; Lymphomas

Indexed keywords

CD30 ANTIGEN; CYTOTOXIC FACTOR; GRANZYME B;

ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL LYMPHOMA; LYMPHOCYTE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; T CELL LYMPHOMA;

EID: 0032994029     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. Harris NL, Jaffe ES, Stein H et al: A revised European-American classification of lymphoid neoplasms. A proposal from the International Lymphoma Study Group. Blood 84: 1361-1392, 1994.
2. Gaulard P, Bourquelot P, Kanavaros P, et al: Expression of the alpha/beta and gamma/delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a subset of γδ T-cell lymphomas. Am J Pathol 137: 617-628, 1990.
3. Stansfeld AG, Diebold J, Noel H, et al: Updated Kiel classification for lymphomas. Lancet 1: 292-293, 1988.
4. Cook C, Krenacs L, Settler-Stevenson M et al: Hepatosplenic T-cell lymphoma: a distinct clinicopathologic entity of cytotoxic γδ T-cell origin. Blood 88: 4265-4274, 1996.
5. Gaulard P, Kanavaros P, Farcet JP, et al: Bone marrow histological and immunohistochemical findings in peripheral T-cell lymphomas: A study of 38 cases. Hum Pathol 22: 331-338, 1991.
6. Kanavaros P, Farcet JP, Gaulard P, et al: Recombinative events of the T-cell antigen receptor & gene in peripheral T-cell lymphomas. J Clin Invest 87: 666-672, 1991.
7. Wong KF, Chan JKC, Matutes E, et al: Hepatosplenic γδ T-cell lymphoma: a distinctive aggressive lymphoma type. Am J Surg Pathol 79: 718-726, 1995.
8. Kanavaros P, Briere J, Emile JF, Gaulard P: Epstein-Barr Virus in T and natural killer Non-Hodgkin's lymphomas. Leukemia 52: S84-S87, 1996.
9. Emile JF, Bouland ML, Haouin C, et al: CD5-,CD56+ T-cell receptor silent peripheral T-cell lymphomas are natural killer cell lymphomas. Blood 87: 1466-1473, 1996.
10. Kanavaros P, Briere J, Lescs MC, Gaulard P: EBV in NHL of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells. J Pathology 178: 297-302, 1996.
11. Kaneko T, Fukuda J, Yoshihara T, et al: Nasal natural killer (NK) cell lymphoma: report of a case with activated NK cells containing Epstein-Barr Virus and expressing CD21 antigen and comparative studies of their phenotype and cytotoxicity with normal NK cells. Br J Haemat. 91: 355-361, 1995.
12. Liu CC, Walsh CM, Young JDE: Perform: structure and function. Immunology Today 16: 194-201, 1995.
13. Smyth MJ, Trapani JA: Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today 16: 202-206, 1995.
14. Salcedo TW, Azzoni L, Wolf SF, Perussia B: Modulation of perform and granzyme messenger RNA expression in human natural killer cells. J Immunol 151: 2511-2520, 1993.
15. Koizumi H, Liu CC, Zheng LM, et al: Expression of perform and serinesterases by human γ/δ T cells. J Exp Med 173: 499-502, 1991.
16. Krenacs L, Wellmann A, Sorhara L, et al: Cytotoxic cell antigen expression in anaplaslic large cell lymphomas of T-and Null-cell type and Hodgkin's disease: evidence for distinct cellular origin. Blood 89: 980-989, 1997.
17. Felgar R, Macon W, Kinney M, et al: TIA-1 Expression in Lymphoid Neoplasms. Identification of Subsets with Cytotoxic T Lymphocyte or Natural Killer Cell Differentiation. Am J Pathol 150: 1893-1900, 1997.
18. Chi-Sing NG, Stephen TH Lo, et al: CD56+ putative natural killer cell lymphomas: production of cytolytic effectors and related proteins mediating tumor cell apoptosis. Hum Pathol 28: 1276-1282, 1997.
19. Daum S, Foss HD, Anagnostopoulos I, et al: Expression of cytotoxic molecules in intestinal T-cell lymphomas. J Pathol 182: 311-317, 1997.
20. Kummer JA, Vermeer MH, Dukers D, et al: Most primary cutaneous CD30-positive lymphoproliferative disorders have a CD4-positive cytotoxic T-cell phenotype. J Invest Dermatol 109(5): 636-640, 1997.
21. Oudejans J, Jiwa M, Kummer J, et al: Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 89: 1376-1380, 1997.
22. De Bruin PC, Kummer JA, Van der valk P, et al: Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue (MALT) localization. Blood 84: 3785-3791, 1994.
23. Mori N, Yatabe Y, Oda K, et al: Expression of perforin in nasal lymphoma. Additional evidence of its natural killer cell derivation. Am J Pathol 149: 699-705, 1996.
24. Jaffe ES, Chan JKC, Su IJ, et al: Report of the Workshop on Nasal and related Extranodal Angiocentric T/Natural Killer Cell Lymphomas. Definitions, differential diagnosis and epidemiology. Am J Surg Pathol 20: 103-111, 1996.
25. Foss HD, Anagnostopoulos I, Araujo I, et al: Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express cytotoxic molecules. Blood 88: 4005-4011, 1996.
26. Boulland ML, Kanavaros P, Weschler J, Casiraghi O, Gaulard P. Cytotoxic protein expression in NK-NHL and in αβ and γδ peripheral T-cell lymphomas. J Pathology 182: 432-437, 1997.
27. Arnulf B, Copie-Bergman C, Delfon-Larne MH, et al: Nonhepatosplenic γδ T-cell lymphoma: A subject of cytotoxic lymphomas with mucosal or skin localization. Blood 91: 1723-1731, 1998.
28. Nalazawa S, Brown AE, Maeno Y, Smith CD, Aikawa M: Malaria-induced increase of splenic gamma delta T cells in humans, monkeys and mice. Exp Parasitol 79: 391-398, 1994.
29. Richmont I, Pritchard GE, Aschcroft T, Corris PA, Walters EH: Distribution of γδ T-cells in the bronchial tree of smokers and non-smokers. J Clin Pathol 46: 926-930, 1993.
30. Haecker G, Kromer S, Falk M, Heeg K, Wagner H, Pfeffer K. Vδ1 + subset of human γδ T cells responds to ligands expressed by EBV-infected Burkitt lymphoma cells and transformed B cells lymphocytes. J lmmunol 149: 3984-3989, 1992.
31. Wang L, Goillot E, Tepper RI. Interleukin-10 inhibits alloreactive cytotoxic T lymphocytes generation in vivo. Cellular Immunol 159: 15Z-159, 1994.
32. Lancki DW, Hsieh CS, Fitsh FW: Mechanisms of lysis by cytotoxic T lymphocyte clones. Lytic activity and gene expression in cloned antigen-specific CD4+ and CD8+ T lymphocytes. J Immunol 146: 3242-3249, 1991.
33. Yasukawa M, Utsonomiya Y, Inoue Y, Kimoura N, Fujita S: Monoclonal proliferation of CD4+ large granular lymphocytes with cytolytic activity. Br J Haematol 91: 419-420, 1995.
34. Leger-Ravet MB, Devergne O, Peuchmaur M, et al: In situ detection of activated cytotoxic cells in follicular lymphomas. Am J Pathol 144: 492-499, 1994.
35. Matures E, Coelho E, Aguado MJ, et al: Expression of TIA-1 and TIA-2 in T-cell malignancies and T-cell lymphocytosis. J Clin Pathol 49: 154-158, 1996.
36. Wȩiss LM, Jaffe ES, Liu XF, Chen YY, Shibata D, Medeiros LJ: Detection and localization of Epstein-Barr viral genomes in angioimmunoblastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. Blood 79: 1789-1795, 1992.
37. Barrett TA, Gajewski TF, Danielpour D, Chang EB, Beagley KW, Bluestone JA: Differential function of intestinal intraepithelial lymphocyte subsets. J Immunol 149: 1124-1130, 1990.
38. Halstensen TS, Brandtzaeg P: Activated T lymphocytes in the celiac lesion: non-proli-ferative activation (CD25) of CD4+ α/β and γ/δ cells in the lamina propria but proliferation (Ki-67) of α/β and γ/δ cells in the epithelium. Eur J Immunol 23: 505-510, 1993.
39. Kanavaros P, Lescs MC, Briere J, et al: Nasal T-cell lymphoma; a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81: 2688-2695, 1993.
40. Oberhuber G, Vogelsang H, Stolte M, Muthenthaler S, Kummer AJ, Radaszkiewcz T: Evidence that intestinal intraepithelial lymphocytes are activated cytotoxic T cells in celiac disease but not in giardiasis. Am J Pathol 148: 1351-1357, 1996.
41. Imai S, Sugiura M, Oikawa O, et al: Epstein-Barr Virus (EBV)-carrying and expressing T-cell lines established from severe chronic active EBV infection. Blood 187: 1446-1457, 1996.
42. Isaacson PG: Intestinal lymphoma and enteropathy. J Pathol 177: 111-113, 1995.
43. Brittenden J, Heys SD, Ross J, Eremin O: Natural Killer cells and cancer. Cancer 77: 1226-1243, 1996.
44. Oudejans JJ, Kummer JA, Jiwa M, et al: Granzyme B expression in Reed-Sternberg cells of Hodgkin s disease. Am J Pathol 148: 233-240, 1996.
45. Frisan T, Sjoberg J, Doldetti R et al: Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin s disease. Blood 86: 1493, 1995.
46. Knecht H, Bachmann E, Brousset P, et al: Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcmoma. Blood 82: 2937, 1993.
47. Ding L, Shevach EM: IL-10 inhibits mitogen induced T-cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 148: 3133, 1992.
48. Matsuda M, Salazar F, Peterson M, et al: Interleukin 10 pretreatment protects target cells from tumor-and allospecific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 180: 2371, 1994.
49. Kerhl JH, Wakefield LM, Roberts AB, et al: Production of Transforming growth factor-beta by human T-lymphocytes and its potential role in the regulation of T-cell growth. J Exp Med 163: 1037, 1986.
50. Rook AH, Kerhl JH, Wakefield LM, et al: Effects of transforming growth factor B on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916, 1986.
51. Newcom SR, Kadin ME, Ansari AA, Diehl V: L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J Clin Invest 83: 1915, 1986.
52. Herbst H, Foss HD, Samol J, et al: Frequent expression of interleukin-10 by Epstein-Barr virus harboring tumor cells of Hodgkin's disease. Blood 87: 2918-2929, 1996.
53. Sun JR, Bird CH, Sutton V, et al: A cytolytic granzyme B inhibitor related to the viral apoptotic regulator cytokine response modifier A is present in cytotoxic lymphocytes. J Biol Chem 277: 27802-27809, 1996.
54. Schroter M, Lewin B, Borner C, Tschopp J: Regulation of fas-apol (CD95) and perforin-mediated lytic pathways of primary cytotoxic T-lymphocytes by the proto-oncogene bcl2. Eur J Immunol 25: 3509-3513, 1995.
55. Jiwa MN, Kanavaros P, Van der Valk P et al: Reed-Sternberg cells in Hodgkin's disease express-frequently c-myc and bcl-2 oncogene products independently of the presence of EBV. J Clin Pathol 46: 211-217, 1993.
56. Wellman A, Otsuki T, Vogelbruch M, Clark HM, Jaffe ES, Raffeld M: Analysis of t(2;5) (p23; q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large cell lymphomas, in order non-Hodgkin's lymphomas of T-cell phenotype and in Hodgkin' s disease. Blood 86: 2321, 1995.
57. Leger-Raver MB, Devergne O, Peuchmaur M, et al: In situ detection of activated cytotoxic cells in follicular lymphomas. Am J Pathol 144: 492-499, 1994.
58. Young LHY, Peterson LB, Wicker LS, Persechini PM, Ding-E Young J: In vivo expression of perforin by CD8+ lymphocytes in autoimmune disease. Studies on spontalneous and adoptively transferred diabetes in nonobese diabetic mice. J Immunol 143: 3994-3999, 1989.
59. Garcia-Sanz JA, MacDonald HR, Jenne DE, Tschopp J, Nabholz M: Cell specificity of granzyme gene expression. J Immunoll 145: 3111-3118, 1990.
60. Bloom ET: Functional importance of CD4+ and CD8+ cells in cytotoxic lymphocytes activity and associated gene expression. Impact on the age-related decline in lytic activity. Eur J Immunol 21: 1013-1017, 1991.
61. Weiss S, Bogen B: B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted Tcells. Proc Natl Acad Sci USA 86: 282-286, 1989.
62. Devergne O, Peuchmaur M, Crevon MC, Trapani JA, Maillot MC, Galanaud P, Emilie D: Activation of cytotoxic cells in hyperplastic lymph nodes from HIV-infected patients. AIDS 5: 1071-1079, 1991.
63. Diaz JI, Edinger MG, Stoler MH, Tubbs RR: Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas. Am J Pathol 139: 503-509, 1991.